Navigation Links
Ardea Biosciences to Present at Two Upcoming Investor Conferences
Date:11/12/2010

o product candidates for the treatment of HIV, RDEA806 and RDEA427, are non-nucleoside reverse transcriptase inhibitors (NNRTIs), which have successfully completed a Phase 2a study in HIV patients and a human micro-dose pharmacokinetic study in healthy volunteers, respectively.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Such statements include, but are not limited to, statements regarding our plans and goals, the expected properties and benefits of RDEA594, BAY 86-9766 (RDEA119), RDEA806, RDEA427 and our other compounds and the timing and results of our preclinical, clinical and other studies.  Risks that contribute to the uncertain nature of the forward-looking statements include risks related to the outcome of preclinical and clinical studies, risks related to regulatory approvals, delays in commencement of preclinical and clinical studies, costs associated with our drug discovery and development programs, and risks related to the outcome of our business development activities, including collaboration or license agreements.  These and other risks and uncertainties are described more fully in our most recently filed SEC documents, including our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, under the headings "Risk Factors."  All forward-looking statements contained in this press release speak only as of the date on which they were made.  We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

(Logo:  http:
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
2. Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting
3. Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference
4. Cardea Technology Inc and Optasia Medical Ltd Announce Plans to Collaborate to Optimize Their Vertebral Fracture Assessment Tools
5. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
6. Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors
7. Ardea Biosciences to Present at the Oppenheimer 21st Annual Healthcare Conference
8. Ardea Biosciences Awarded a $733,438 Grant from the U.S. Government Under the Patient Protection and Affordable Care Act
9. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
10. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
11. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... year, Formedix celebrated its partnership with ... management solutions for clinical trials. The company launched its ... capture (EDC) and clinical data management. Formedix, a renowned ... TrialMaster to its Transform for EDC product line. This ... is being released this week, in response to market ...
(Date:7/23/2014)... , July 23, 2014 ... company of Trendlines Agtech , announced it ... Israel,s leading agricultural thermoplastics applications ... Valentis,s technology combines nanocrystalline cellulose (NCC), a ... with additional nanoparticles to produce highly improved polymeric ...
(Date:7/23/2014)... July 23, 2014 Shire ... the global specialty biopharmaceutical company, and ArmaGen, a ... worldwide licensing and collaboration agreement for AGT-182, an ... treatment of both the central nervous system (CNS) ... (MPS II). This collaboration strengthens Shire,s rare disease ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 With the ability ... HD resolution for more than 15 minutes, Fastec Imaging has ... world of high speed imaging. “Finally, a high speed camera ... we use in our everyday lives.” proclaims Matt Kearney, VP ... has always been to demystify and simplify the traditionally complicated ...
Breaking Biology Technology:Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 2Formedix and OmniComm Systems® Partnership Strengthened with the Release of Enhanced TrialMaster® Integration for EDC Build 3Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 2Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 3Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 4Shire Enters Strategic Licensing and Collaboration Agreement With ArmaGen 5Fastec Imaging Introduces the First High Speed Camcorder 2Fastec Imaging Introduces the First High Speed Camcorder 3
... AVIV, Israel, September 23 InspireMD, Ltd.,announced today ... its study of,MGuard(TM) coronary stent in acute myocardial ... Study) is designed to evaluate,the safety and efficacy ... infarction. The first 3 patients were implanted,successfully with ...
... Affitech AS, the Norwegian human,antibody therapeutics company, ... milestone in its research and licensing collaboration ... against an unnamed oncology,target. Affitech has successfully ... that included its proprietary antibody library and ...
... KNDL ), a,leading, global full-service clinical research ... Kendle, PharmD, will,participate in the annual UBS Global ... the Grand Hyatt New York, Park Avenue at ... presentation is,scheduled for Wednesday, September 24 at 9:30 ...
Cached Biology Technology:InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 2InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results 3Affitech Announces Second Milestone in Roche Antibody Discovery Collaboration 2
(Date:7/23/2014)... A 2C increase in temperature around the world by ... the Intergovernmental Panel on Climate Change (IPCC), may be ... processes involved in the growth of forage plants such ... for livestock grazing in tropical countries such as Brazil., ... researchers in the Department of Biology at the Ribeiro ...
(Date:7/23/2014)... will play an increasingly important role in carbon and ... zones expand, according to research published this week in ... . , University of British Columbia researchers plumbed the ... to chart how microbial community metabolism changes as oxygen ... detailed picture of how SUP05 a bacterial group ...
(Date:7/23/2014)... will publish the International Journal of Fuzzy Systems ... Taiwan Fuzzy Systems Association (TFSA). The cooperation will allow ... area of fuzzy research., The International Journal of ... that deal with the theory, design and application of ... theory systems ranging from hardware to software. Launched in ...
Breaking Biology News(10 mins):An increase in temperature by 2050 may be advantageous to the growth of forage plants 2An increase in temperature by 2050 may be advantageous to the growth of forage plants 3An increase in temperature by 2050 may be advantageous to the growth of forage plants 4Research charts the ecological impact of microbial respiration in the oxygen-starved ocean 2
... an advance that could help ease the antibiotic drought, ... test that enlists pinhead-sized worms in efforts to discover ... ACS Chemical Biology , a monthly journal. ... that existing methods for identifying germ-fighting drugs involve adding ...
... diplomats and campaigners prepare to attend the COP15 conference ... battle against climate change in one of the most ... increasingly complex territory of climate negotiations is being revealed ... IOP Publishing,s Environmental Research Letters . ...
... A compound initially isolated from a soft coral ( Capnella ... scientists to develop a new set of treatments for neuropathic ... nervous system. Currently this form of pain is very ... or even opioids like morphine) and novel treatments are urgently ...
Cached Biology News:Climate change poker: The barriers which are preventing a global agreement 2Neuropathic pain: The sea provides a new hope of relief 2
... 19 x 29 cm, 1. One ... staining of Coomassie Blue or silver-stain gels ... blots for high sensitivity ECL detection and ... volume, and processing time.Proven design for consistent, ...
Cytidine 5'-Triphosphate, Sodium (CTP), 1 g. Category: Nucleotides & Enzymes & Biochemicals, Nucleotides, Additional Nucleotide Products....
... Plus Western Blotting Reagent Pack, 1. ... detection of membrane-bound mouse and rabbit primary ... PVDF membranes. Detection reagents are not included, ... with ECL Plus. Category: Blotting & ...
... FHS-LVF and CVD-Diffuse We've combined our ... to create the world's first notch filter ... bandpass. Each filter features an excellent transmission ... These filters -- with interference coatings applied ...
Biology Products: